Use of FSH levels
- 01 Dec 2023
- 1 Minute to read
- Print
- PDF
Use of FSH levels
- Updated on 01 Dec 2023
- 1 Minute to read
- Print
- PDF
Article summary
Did you find this summary helpful?
Thank you for your feedback
1. NICE recommendations
NICE says consider using a serum FSH test to confirm menopause only in:
- People aged 40–45 years with menopause symptoms, including a change in their menstrual cycle.
- In people <40 years in whom menopause is suspected.
2. How to perform FSH testing
- Serial measures should be undertaken, and most guidelines recommend checking two FSH blood samples taken 4–6 weeks apart.
- If there are still periods, a blood test for FSH should be taken on day 2-3 of the cycle.
- FSH levels should not be checked in a woman already using HRT, combined contraception or high dose progestogen.
3. Interpreting FSH results
- Levels of FSH >30IU/L are generally considered to be elevated and is the cut-off used by both NICE and the British Menopause Society. The ESHRE guideline suggests a slightly lower cut-off of >25IU/L.
- Levels of FSH fluctuate markedly on virtually a daily basis during the perimenopause and as a result, their diagnostic use is severely limited during this time. After menopause, FSH levels become persistently raised.
- The FSRH states that a single elevated serum FSH level (>30IU/L) indicates a degree of ovarian insufficiency, but not necessarily sterility.
References and Further Information
- Mangement of the Menopause. Sixth edition. Hillard T, Abernethy K, Hamoda H et al British Menopause Society. 2017.
- NICE Menopause: diagnosis and management. Section 1.2.4. Last updated December 2019.
- NICE CKS guidance. Diagnosis. When should I suspect a diagnosis of menopause or perimenopause? Last revised September 2022.
- Menopause Practice Standards produced by the British Menopause Society (BMS), Royal College of Obstetricians and Gynaecologists (RCOG), Society for Endocrinology (SfE), Faculty of Sexual and Reproductive Health (FSRH), Faculty of Pharmaceutical Medicine (FPM) and Royal Pharmaceutical Society (RPS) 2022.
- ESHRE guideline. Webber L, Davies M, Anderson R et al. European Society for Human Reproduction and Embryology (ESHRE) guideline group on POI. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016.
- Baber R, Panay N, Fenton A et al. IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. Available on page 113. 2016.
- Panay N, Anderson A, Nappi R et al. Premature ovarian insufficiency: an International Menopause White Paper. Climacteric. 2020.
- FSRH guidance. Contraception for women over 40 years. August 2017. Last mended July 2023. Page 26
- National Institute for Health and Care Excellence. Guideline. Menopause (update). Draft for consultation, Nov 2023.
Was this article helpful?